OK...
Thanks.
But, to answer your question:
"Not sure where your getting your numbers from but just yesterday Harvey reiterated projected cash at FYE of around $46mm"
Those numbers are fine. But, look at it this way. What were ALL the analysts saying in April about Ariad's ~$40 million cash position? They were saying the company needed financing.
We will be in the same exact position next April with cash right around those levels if they do not receive funding.
All I am saying is I think this "go it alone" mentality is a thing of the yester-year for biotech. It makes sense, IMO, to partner, and have large pharma "hold your hand" for a piece of the money.